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Abstract
Background: The pathogenesis of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) is associated
with the accumulation of aggregated forms of the a-synuclein (aSN) protein. An early event in the
neuropathology of PD and DLB is the loss of synapses and a corresponding reduction in the level of synaptic
proteins. However, the molecular mechanisms involved in synapse damage in these diseases are poorly
understood. In this study the process of synapse damage was investigated by measuring the amount of
synaptophysin, a pre-synaptic membrane protein essential for neurotransmission, in cultured neurons incubated
with aSN, or with amyloid-b (Ab) peptides that are thought to trigger synapse degeneration in Alzheimer’s disease.
Results: We report that the addition of recombinant human aSN reduced the amount of synaptophysin in
cultured cortical and hippocampal neurons indicative of synapse damage. aSN also reduced synaptic vesicle
recycling, as measured by the uptake of the fluorescent dye FM1-43. These effects of aSN on synapses were
modified by interactions with other proteins. Thus, the addition of bSN reduced the effects of aSN on synapses.
In contrast, the addition of amyloid-b (Ab)1-42 exacerbated the effects of aSN on synaptic vesicle recycling and
synapse damage. Similarly, the addition of aSN increased synapse damage induced by Ab1-42. However, this effect
of aSN was selective as it did not affect synapse damage induced by the prion-derived peptide PrP82-146.
Conclusions: These results are consistent with the hypothesis that oligomers of aSN trigger synapse damage in
the brains of Parkinson’s disease patients. Moreover, they suggest that the effect of aSN on synapses may be
influenced by interactions with other peptides produced within the brain.
Background
Parkinson’s disease (PD) is a neurodegenerative motor
disorder affecting up to 2% of the population over the
age of 65. Although it is characterised by the presence
of bradykinesia, resting tremor and rigidity, up to 88%
of patients also show significant psychiatric and auto-
nomic symptoms [1]. The most common of these non-
motor symptoms are Parkinson’s disease dementia
(PDD), with a cumulative prevalence ranging between
50 and 75% of cases [2] and dementia with Lewy Bodies
(DLB), a similar condition to PDD except that dementia
rather than motor symptoms are primary. DLB is the
second most common cause of dementia after Alzhei-
mer’s disease (AD) and is characterised by progressive
cognitive decline and parkinsonism [3]. Currently, there
is no long-term cure for PD, PDD or DLB.
The major histopathological hallmark of PD, PDD and
DLB is the alpha-synuclein (aSN) positive intraneuronal
inclusion known as a Lewy body (LB). Although the pre-
s e n c eo fL B si nt h es u b s t a n t i an i g r ai sd i a g n o s t i cf o rP D ,
aSN pathology is also seen in multiple extranigral
regions and may account for the wide range of non-
motor symptoms observed. The detailed mechanisms
underlying the pathological changes in PD are not known
but aSN is thought to play a central role. aSN is predo-
minantly expressed in central nervous system neurons
where it is localised to pre-synaptic terminals, regulates
synaptic vesicle formation and neurotransmitter release
[4,5] and can affect synaptic plasticity during learning [6].
However, recent evidence suggests that small oligomer
aggregates of aSN accumulate at the pre-synaptic mem-
brane and trigger synapse degeneration in PD and DLB
[7-9]. The transfer of aSN to neighbouring neurons
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aSN pathology through the brain similar to the staging
of tau pathology in AD [12]. The loss of synapses in the
hippocampus is characteristic of the PD patients that
develop dementia [13] and in a rat model of a-synuclei-
nopathy, synaptic degeneration preceded neuronal loss
[14]. Thus, synapse degeneration is a common feature
observed in PD, PDD and DLB.
There has been little study of the molecular mechan-
isms underpinning aSN induced synapse degeneration
in these disorders. To investigate these mechanisms the
effect of aSN on synapses in cultured cortical or hippo-
campal neurons was determined by quantifying the
amount of synaptophysin using an enzyme-linked
immunoassay (ELISA) [15]. Synaptophysin is a pre-
synaptic membrane protein associated with recycling
vesicles that are essential for neurotransmission [16,17]
and the amount of synaptophysin has been used to
access synaptic density in the brain [18-20] and cultured
neurons [15]. An understanding of the molecular
mechanisms that underlie aSN-induced synapse damage
may help identify drugs that reduce this process.
Results
aSN causes synapse damage
The synapse degeneration in PD and DLB that is asso-
ciated with oligomers of aSN [7-9] was modelled in
vitro. The addition of recombinant human aSN reduced
the synaptophysin content of cortical neurons in a dose-
dependent manner (Figure 1A). The synaptophysin
content was reduced to 50% of control neurons (EC50)
following the addition of 500 nM aSN. This effect of
aSN on synapses occurred at concentrations that did
not kill neurons; for example, the addition of 10 μM
aSN reduced the synaptophysin content of cortical neu-
rons by greater than 80% without affecting their viability
as measured by thiazolyl blue tetrazolium (100% cell
survival ± 8 compared with 96% ± 6, n = 9, P = 0.22).
Similarly, immunoblots showed that aSN reduced the
amount of synaptophysin in neuronal extracts without
affecting the amount of b-actin (Figure 1B). The addi-
tion of bSN, another member of the synuclein family of
proteins [6], did not affect the synaptophysin content of
cortical neurons. We found that the addition of aSN,
but not bSN, also reduced the amount of synaptophysin
in hippocampal neurons (Figure 1C), an observation
consistent with a report that the loss of synapses in the
hippocampus is characteristic of the PD patients that
develop dementia [13].
aSN reduced synaptic vesicle recycling
The uptake of FM1-43, a fluorescent dye that is taken
up into synaptic vesicles, was used as a measure of
synaptic vesicle recycling and hence neurotransmission
[21]. Here we report that the uptake of FM1-43 by cor-
tical neurons was reduced following the addition of
aSN, but not after the addition of bSN (Figure 2). This
effect of aSN was observed at lower concentrations than
that required to reduce the synaptophysin content of
neurons and the concentration of aSN required to
reduce synaptic vesicle recycling by 50% was approxi-
mately 30 nM.
bSN reduced aSN-induced synapse damage
Although transgenic mice studies showed that the
expression of bSN reduced neurodegeneration in mice
expressing human aSN [22,23], the molecular mechan-
isms underlying the interactions between aSN and bSN
a r eu n k n o w n .W ef o u n dt h a tp r e - m i x i n gaSN with an
excess of bSN (1:10) reduced the aSN-induced loss of
synaptophysin in cortical neurons, whereas pre-mixing
aSN with human serum albumin (1:10) had no affect
(Figure 3). As this result may have been caused by a
Figure 1 aSN triggered the loss of synaptophysin from
cultured neurons. (A) The synaptophysin content of cortical
neurons incubated for 24 hours with aSN (●)o rbSN (○) as shown.
Values shown are the mean amount of synaptophysin (units) ± SD,
n = 15. (B) Immunoblots showing the amount of synaptophysin and
b-actin in extracts from cortical neurons that had been incubated
for 24 hours with aSN as shown. (C) The synaptophysin content of
hippocampal neurons incubated for 24 hours with aSN (●)o rbSN
(○) as shown. Values shown are the mean amount of synaptophysin
(units) ± SD, n = 12.
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pre-treated with 10 μM bSN, washed and then incu-
bated with aSN. Pre-treatment of neurons with bSN did
not affect the loss of synaptophysin induced by aSN
(data not shown).
Ab1-42 enhanced aSN-induced synapse damage
The amyloid hypothesis of Alzheimer’s disease (AD)
pathogenesis maintains that the primary event is the
production of neurotoxic amyloid-b (Ab) peptides fol-
lowing the proteolytic cleavage of the amyloid precursor
protein into different sized fragments [24,25]. These frag-
ments include Ab1-42 which is widely regarded as a major
pathogenic species in AD [26]. Since recent reports
showed that aSN and Ab1-42 co-exist in heterologous oli-
gomers [27,28] the effect of Ab1-42 on aSN-induced loss
of synaptophysin was examined by pre-mixing the two
peptides. The addition of Ab1-42 in the ratio (1:50)
increased aSN-induced synapse damage (Figure 4A).
Thus, while the EC50 of aSN alone was 500 nM, the EC50
of Ab1-42:aSN (1:50) was 25 nM. These concentrations of
Ab1-42 did not affect synapses when added on their own.
In contrast, pre-mixing aSN with the control peptide
Ab42-1 (1:50) did not affect aSN-induced loss of synapto-
physin. Since the predominant Ab species found within
the brain is Ab1-40 [29] the effect of Ab1-40 on aSN was
Figure 2 aSN reduced synaptic vesicle recycling. The amount of
the fluorescent dye (FM1-43) taken up by synaptic vesicles in cortical
neurons that had been incubated for 24 hours with different
concentrations of aSN (●)o rbSN (○) as shown and stimulated with
ACh for 10 minutes. Values shown are the mean % fluorescence
(where 100% = fluorescence in control cortical neurons) ± SD, n = 15.
Figure 3 bSN reduced the aSN-induced loss of synaptophysin.
The synaptophysin content of cortical neurons incubated with varying
concentrations of aSN (●), aSN premixed with bSN (1:10)(□)o raSN
premixed with human serum albumin (1:10)(■) for 24 hours. Values
shown are the mean amount of synaptophysin (units) ± SD, n = 12. (*)
= amount of synaptophysin significantly higher than in neurons
incubated with the same concentration of aSN alone (P < 0.01).
Figure 4 Ab1-42 enhanced the aSN-induced loss of
synaptophysin. (A) The synaptophysin content of cortical neurons
incubated for 24 hours with varying concentrations of aSN (●), aSN
premixed with Ab1-42 (50:1) (■)o raSN premixed with Ab42-1 (50:1)
(□). Values shown are the mean amount of synaptophysin (units) ±
SD, n = 18. (*) = amount of synaptophysin significantly lower than
in neurons incubated with the same concentration of aSN alone
(P < 0.01). (B) The synaptophysin content of cortical neurons pre-
treated for 1 hour with control medium (●) or 1 nM Ab1-42 (○) and
incubated for 24 hours with aSN as shown. Values shown are the
mean amount of synaptophysin (units) ± SD, n = 12. (C) The
synaptophysin content of cortical neurons incubated for 24 hours
with aSN (●), aSN premixed with 7PA2-CM (■)o raSN premixed
with CHO-CM (□). Values shown are the mean amount of
synaptophysin (units) ± SD, n = 12. (*) = amount of synaptophysin
significantly lower than in neurons incubated with the same
concentration of aSN alone (P < 0.01).
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in the synaptophysin content of cortical neurons incu-
bated with aSN and neurons incubated with Ab1-40/aSN
(1:50) (data not shown). These results may have been
caused by a direct effect of Ab1-42 on the neurons. Our
observation that pre-treatment of cortical neurons with
1n MA b1-42 did not affect aSN-induced loss of synapto-
physin (Figure 4B) suggested that Ab1-42 did not sensitise
neurons to the effects of aSN.
The ability of synthetic Ab peptides to self associate
results in a mixture of physical complexes ranging from
small soluble oligomers to large fibrils. Since the
dynamic nature of Ab aggregation means that it is diffi-
cult to ascribe biological function to specific Ab assem-
blies using synthetic peptides, the activity of naturally
derived, stable Ab oligomers was also examined. We
found that pre-mixing aSN with 7PA2-conditioned
medium (7PA2-CM), which contained naturally secreted
stable Ab oligomers [30,31], increased the aSN-induced
loss of synaptophysin in cortical neurons (Figure 4C). In
contrast, pre-mixing aSN with CHO-CM had no effect.
Ab enhanced aSN-induced inhibition of synaptic vesicle
recycling
The addition of Ab oligomers also affected aSN-induced
inhibition of synaptic vesicle recycling. Thus, pre-mixing
aSN with 7PA2-CM enhanced aSN-induced inhibition
of FM1-43 uptake into synapses. The concentration of
aSN alone required to reduce synaptic vesicle recycling
by 50% was 30 nM, while the concentration of aSN that
had been mixed with 7PA2-CM to have a similar level
of effect was 1 nM (Figure 5).
aSN enhanced Ab1-42-induced synapse damage
Next we examined whether non-toxic concentrations of
aSN affected Ab1-42-induced loss of synaptophysin.
Here we show that pre-mixing Ab1-42 with aSN
increased the Ab1-42-induced loss of synaptophysin from
neurons (Figure 6). Thus, while the EC50 of Ab1-42 alone
was 50 nM, the EC50 of aSN:Ab1-42 (2:1) was 5 nM. In
contrast, the addition of bSN (2:1) did not affect Ab1-42-
induced loss of synaptophysin. Pre-treatment of cortical
neurons with 10 nM aSN did not affect Ab1-42-induced
loss of synaptophysin (data not shown). We also sought
to determine if aSN affected another peptide that
caused synapse damage. Synapse degeneration is a fea-
ture of human and experimental prion diseases [32,33]
which was modelled by the addition of the prion-derived
peptide PrP82-146 to cortical neurons [15]. As shown in
Figure 6B, there was no difference in the synaptophysin
content of cortical neurons incubated with PrP82-146
and those incubated with a combination of aSN/PrP82-
146 (2:1).
aSN did not affect the accumulation of Ab1-42 in synapses
We explored the possibility that aSN increased the
binding of Ab1-42 to synapses as an explanation of the
effect of aSN on Ab1-42-induced loss of synaptophysin.
Time course studies showed that Ab1-42 accumulated in
synaptosomes isolated from cortical neurons after 1
hour. Therefore cortical neurons were incubated with
100 nM biotinylated Ab1-42, or 100 nM biotinylated-
Ab1-42 that had been pre-mixed with 500 nM aSN for
1 hour. The amount of biotinylated Ab1-42 found in
synaptosomes isolated from these neurons was not
altered by pre-mixing with aSN (Figure 7A), indicating
that aSN did not alter the binding, or trafficking of
Ab1-42 to synapses. The effect of Ab1-42 on the accumu-
lation of aSN in synapses was also examined. Cortical
neurons were incubated with 200 nM aSN, or a combi-
nation of 4 nM Ab1-42 and 200 nM aSN (1:50), for
1 hour and synaptosomes prepared. Immunoblots
showed that the amount of aSN found within synapses
was not affected by presence of Ab1-42 (Figure 7B).
Discussion
T h el o s so fs y n a p s e si sap r o m i n e n tf e a t u r eo fm a n y
neurodegenerative diseases including AD, PDD and
LBD. The main mediators of neuropathology in PDD
Figure 5 Ab1-42 enhanced the aSN-induced inhibition of
synaptic vesicle recycling. The amount of the fluorescent dye
(FM1-43) taken up into synaptic vesicles in cortical neurons that had
been incubated for 24 hours with different concentrations of aSN
(●), or with aSN that had been premixed with either 7PA2-CM (■)
or with CHO-CM (□) as shown and stimulated with ACh for 10
minutes. Values shown are the mean % fluorescence (where 100%
= fluorescence in vehicle treated cortical neurons) ± SD, n = 18. (*)
= Fluorescence significantly lower than in neurons incubated with
the same concentration of aSN alone (P < 0.01).
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in this study the addition of aSN impaired synapse
function and triggered a loss of synaptophysin from cor-
tical neurons. These effects occurred at concentrations
of aSN that did not affect neuronal survival; an observa-
tion consistent with reports that synapse degeneration
preceded neuronal loss in a rat model of a-synucleino-
pathy [14]. A reduction in the synaptophysin content of
hippocampal neurons was observed after incubation
with aSN, consistent with reports that a loss of synapses
in the hippocampus is characteristic of the PD patients
that develop dementia [13].
The addition of bSN did not affect synapses indicating
that synaptic defects were dependent upon the specific
amino acid sequence of aSN. Recent reports from a
transgenic mouse model of PD showed that the expres-
sion of bSN reduced the accumulation of aSN and neu-
rodegeneration in mice expressing human aSN [22,23].
Another study showed that bSN formed mixed oligo-
mers with aSN [34]. In this study we showed that
mixing with bSN reduced the loss of synaptophysin
induced by aSN; results consistent with the idea that
molecular interactions between aSN and bSN affect the
toxicity of aSN.
Approximately 25% of AD patients develop parkinson-
ism and 50% of PD patients develop AD-type dementia
after 65 years of age [35]. In addition, 70% of patients
with sporadic AD display aSN-positive, LB-like inclu-
sions in the amygdala and limbic structures [36-38]. The
loss of synapses that occurs in AD is associated with the
production of Ab oligomers [39-41]. Both Ab and aSN
accumulate in the brain in DLB [3] and levels of aSN
are increased in AD [42], observations which suggest
that interactions between aSN and Ab affect the patho-
genesis of AD, PDD and DLB [43].
The addition of small amounts of Ab1-42,w h i c hh a d
no effect on synapses on their own, increased the effects
of aSN on synapses. Critically pre-treatment with Ab1-42
Figure 6 aSN enhanced the Ab1-42-induced loss of
synaptophysin. (A) The synaptophysin content of cortical neurons
incubated for 24 hours with Ab1-42 (●)A b1-42 premixed with aSN
(1:2) (■)o rA b1-42 premixed with bSN (1:2) (□). Values shown are the
mean amount of synaptophysin (units) ± SD, n = 15. (*) = amount
of synaptophysin significantly lower than in neurons incubated with
the same concentration of Ab1-42 alone (P < 0.01). (B) The
synaptophysin content of cortical neurons incubated for 24 hours
with PrP82-146 (●) or PrP82-146 that had been premixed with aSN
(1:5) (○). Values shown are the mean amount of synaptophysin
(units) ± SD, n = 15.
Figure 7 aSN did not affect the accumulation of Ab1-42 in
synapses. (A) The amount of biotinylated-Ab1-42 found in
synaptosomes derived from cortical neurons incubated for 1 hour
with 100 nM Ab1-42 (□) or 100 nM Ab1-42 that had been pre-mixed
with 500 nM aSN (■). Values shown are the mean amount of Ab1-42
expressed as a % of the amount added ± SD, n = 12. (B)
Immunoblot showing the amount of aSN in synaptosomes
collected from cortical neurons incubated with 200 nM aSN alone
or with 200 nM aSN pre-mixed with Ab1-42 (50:1).
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of aSN and while we cannot exclude the possibility of a
transient sensitizing effect of Ab1-42, our results suggest
that direct interactions between Ab1-42 and aSN
increased the toxicity of aSN. The studies using syn-
thetic Ab1-42 peptides were complimented by studies
using 7PA2-CM containing naturally secreted, stable Ab
oligomers [30,31]. Pre-mixing with 7PA2-CM also
increased the effects of aSN upon synaptic vesicle recy-
cling and synapse damage. Relatively small amounts of
Ab1-42 (1:50) were required to facilitate the aSN-
induced loss of synaptophysin suggesting that Ab1-42
seeded the formation of toxic aSN oligomers; an obser-
vation consistent with reports that Ab promotes the
aggregation of aSN in transgenic mice [44]. Conversely,
the addition of non-toxic concentrations of aSN
increased Ab1-42-induced loss of synaptophysin.
Ab1-42 exists in multiple forms from small soluble
toxic oligomers to large insoluble amyloid fibrils. As the
toxicity of Ab1-42 is affected by its state of aggregation
[45,46] the addition of aSN may stabilize Ab1-42 oligo-
mers in a toxic configuration. Mixing aSN with Ab1-42
did not increase the amount of aSN or Ab1-42 found
within synapses showing that the increased toxicity of
hetero-oligomers was not due to increased binding of
Ab1-42 or aSN to synapses.
Although Ab1-42 is considered to be the major neuro-
toxin generated in AD [47-50] other Ab fragments are
produced [24,25,51] and since Ab1-40 is the predominant
Ab species formed in AD [29,52] the effect of Ab1-40 on
aSN-induced loss of synaptophysin was also tested. We
found that aSN did not affect the reduction in synapto-
physin in response to Ab1-40,n o rd i dA b1-40 affect the
reduction in synaptophysin induced by aSN. Synapse
degeneration is also a feature of human and experimen-
tal prion diseases [32,33] and the prion-derived peptide
PrP82-146 triggered a reduction in synaptophysin in
cortical neurons [15]. Although PrP82-146 has similar
biophysical properties to Ab1-42 in that it adopts a
b-helix-rich conformation, forms oligomers and fibrils
which are protease resistant [53], aSN did not affect
PrP82-146-induced loss of synaptophysin.
Conclusions
We conclude that the addition of aSN reduced the
synaptophysin content of cultured cortical and hippo-
campal neurons, a model that mimics the synapse
damage observed in PDD and DLB. The effect of aSN
was modified by other proteins found in the central ner-
vous system including bSN which reduced the effects of
aSN, and Ab1-42 which increased the effects of aSN
on synapses. Conversely, aSN increased the effects of
Ab1-42 on synapses. Our results suggest that interactions
between the synucleins and Ab peptides may affect
synapses in AD, PDD and Lewy body disorders.
Methods
Primary neuronal cultures
Cortical neurons were prepared from the brains of
mouse embryos (day 15.5) as described [15]. Neurons
were plated at 2 × 10
5 cells/well in pre-coated 48 well
plates (5 μg/ml poly-L-lysine) in Ham’sF 1 2( P A A )
containing 5% foetal calf serum (FCS) for 2 hours. Cul-
tures were shaken (600 r.p.m for 5 minutes) and non-
adherent cells removed by 3 washes in PBS. Neurons
were grown in neurobasal medium (NBM) containing
B27 components (PAA) for 10 days. Immunohistochem-
istry showed that the cells were greater than 97% neuro-
filament positive. Fewer than 3% of cells stained for glial
fibrillary acidic protein (astrocytes) or for F4/80 (micro-
glial cells). Hippocampal neurons were prepared from
the brains of adult mice as described [54]. Hippocampi
w e r ed i s s e c t e df r o mb r a i n sa n dt r i t u r a t e di nH a m ’s
F12 containing 5% FCS, 0.35% glucose, 0.025% trypsin,
and 0.1% type IV collagenase. After 30 minutes at 37°C,
the cells were triturated and the cell suspension was
passed through a 100 μM cell strainer. Cells were col-
lected, washed twice and plated at 2 × 10
5 cells/well in
48 well plates (pre-coated with poly-L-lysine). After
24 hours cultures were shaken (600 r.p.m for 5 minutes)
to remove non-adherent cells, washed twice and the
remaining neurons were cultured in NBM/B27 and
10 ng/ml glial-derived neurotrophic factor (Sigma) for
7 days. Neurons were incubated with peptides for
24 hours and the amount of synaptophysin in cell
extracts measured.
Cell extracts
Neurons were washed 3 times with PBS and homogenised
in a buffer containing 150 mM NaCl, 10 mM Tris-HCl,
pH 7.4, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium
deoxycholate, 0.2% sodium dodecyl sulphate (SDS) and
mixed protease inhibitors (4-(2-Aminoethyl) benzenesul-
fonyl fluoride hydrochloride (AEBSF), Aprotinin, Leupep-
tin, Bestain, Pepstatin A and E-46) (Sigma) at 10
6 cells/ml.
For immunoblots cells were homogenised in extraction
buffer (as above) at 10
7 cells/ml and digested with DNAse
(Sigma) for 1 hour at 37°C. Cell debris was removed by
low speed centrifugation (300 × g for 5 minutes).
Synaptophysin ELISA
The amount of synaptophysin in neuronal extracts was
measured by ELISA [15]. Briefly, the capture mAb was
anti-synaptophysin MAB368 (Millipore). Samples were
added for 1 hour and bound synaptophysin was detected
using rabbit polyclonal anti-synaptophysin (Abcam)
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vidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol
phosphate. Absorbance was measured on a microplate
reader at 405 nm and the synaptophysin content of
samples was expressed as units where 100 units was
defined as the amount of synaptophysin in untreated
neurons.
Synaptic vesicle recycling
The fluorescent styryl dyeF M 1 - 4 3( B i o t i u m )t h a ti s
readily taken up into synaptic recycling vesicles [55] was
used to determine synaptic activity as described [21].
Treated neurons were incubated with 1 μg/ml FM1-43
and 1 μM acetylcholine (ACh) for 10 minutes, washed
5 times in ice cold PBS and solubilised in methanol at
1×1 0
6 neurons/ml. Soluble extracts were transferred
into Sterlin 96 well black microplates and fluorescence
was measured using excitation at 480 nm and emission
at 625 nm. Background fluorescence was subtracted and
samples were expressed as “% fluorescence” where 100%
fluorescence was defined as the amount of fluorescence
in untreated neurons incubated with FM1-43 and ACh.
Synaptosome preparations
Synaptosomes were prepared on a discontinuous
Percoll gradient [56]. Briefly, 10
6 cortical neurons were
homogenized at 4°C in 1 ml of SED solution (0.32 M
s u c r o s e ,5 0m MT r i s - H C l ,p H7 . 2 ,1m ME D T A ,a n d
1 mM dithiothreitol, and centrifuged at 1000 × g for
10 minutes. The supernatant was transferred to a gradi-
ent of 3, 7, 15, and 23% Percoll in SED solution and
centrifuged at 16,000 × g for 30 minutes at 4°C. The
synaptosomes were collected from the interface of the
15% and 23% Percoll steps. The fraction was washed
twice (16,000 × g for 30 minutes at 4°C) and suspended
in extraction buffer containing 150 mM NaCl, 10 mM
Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% sodium dodecyl
sulphate and mixed protease inhibitors.
Biotinylated Ab1-42 ELISA
The amounts of biotinylated Ab1-42 in extracts were
determined by ELISA. Nunc Maxisorb Immunoplates
were coated with 1 μg/ml protein A (Innova) followed
by 0.1 μg/ml mAb reactive to amino acids 1 to 16 of
b-amyloid (clone 6E10 - Signet) and blocked with 5%
milk powder. Samples were boiled in 0.2% SDS, cooled
and incubated for 1 hour. Biotinylated Ab1-42 was
detected with extravidin-alkaline phosphatase and 1 mg/
ml 4-nitrophenyl phosphate (Sigma). Absorbance was
measured on a microplate reader at 405 nm and results
were calculated by reference to a standard curve gener-
ated form serial dilutions of biotinylated Ab1-42.
Western analysis
Samples were mixed with an equal volume of Laemmli
buffer, boiled, and subjected to electrophoresis on a 15%
polyacrylamide gel (Invitrogen). Proteins were trans-
ferred onto a Hybond-P PVDF membrane (Amersham
Biotech) by semi-dry blotting. Membranes were blocked
using 10% milk powder; synaptophysin was detected
using a mouse monoclonal antibody (mAb) anti-synap-
tophysin SY38 (Abcam), b-actin was detected by incuba-
tion with a mouse mAb (clone AC-74, Sigma) and
human aSN was detected by incubation with mAb 211
raised against amino acids 121 to 125 of human aSN
(Santa Cruz Biotech). These were visualised using a
combination of biotinylated secondary antibodies
(Dako), extravidin-peroxidase and an enhanced chemilu-
minescence kit.
Peptides
Recombinant human aSN and bSN were purchased from
Sigma. Synthetic peptides containing the amino acids 1
to 42 (Ab1-42) or 1 to 40 (Ab1-40) of the Ab protein, bioti-
nylated-Ab1-42 and a control peptide consisting of amino
acids 1 to 42 in reverse order (Ab42-1)w e r eo b t a i n e d
from Bachem. Peptides containing amino acids 82 to 146
of the human PrP protein (PrP82-146) and was a gift
from Professor Salmona (Mario Negri, Milan). Ab pep-
tides were first dissolved in hexafluoroisopropanol, lyo-
philised and subsequently solubilised and stored at 1 mM
in DMSO. Stock solutions of peptides were stored at 1
mM, thawed on the day of use and diluted/mixed in
NBM for 1 hour at 37°C. Dilutions/mixtures were sub-
jected to vigorous shaking (Disruptor Genie, full power
f o r1 0m i n u t e s )b e f o r et h e yw e r ea d d e dt on e u r o n s .C h i -
nese hamster ovary (CHO) cells stably transfected with a
cDNA encoding APP751 containing the Val717Phe famil-
ial AD mutation (referred to as 7PA2 cells) were cultured
in DMEM with 10% FCS [30,31]. Conditioned medium
from these cells contains stable Ab oligomers (7PA2-
CM). Conditioned medium from non-transfected CHO
cells (CHO-CM) was used as controls. These were mixed
with peptides and subjected to vigorous shaking (as
above), diluted in NBM and added to neurons.
Statistical Analysis
Differences between treatment groups were determined
by 2 sample, paired T-tests. For all statistical tests signif-
icance was set at the 1% level.
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